Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target reduced by research analysts at Morgan Stanley from $128.00 to $118.00 in a report released on Friday. The brokerage currently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price indicates a potential upside of 1.79% from the company’s current price.
A number of other analysts have also recently commented on ALNY. Leerink Swann boosted their price objective on Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the company a “market perform” rating in a research report on Thursday, January 25th. B. Riley assumed coverage on Alnylam Pharmaceuticals in a research report on Wednesday, November 1st. They issued a “buy” rating and a $240.00 price objective for the company. Piper Jaffray Companies restated a “buy” rating and issued a $182.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Sunday, January 7th. Needham & Company LLC restated a “buy” rating and issued a $152.00 price objective (up from $125.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Finally, Barclays boosted their price objective on Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the company an “overweight” rating in a research report on Wednesday, November 8th. Three analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $126.98.
Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) traded down $0.40 during mid-day trading on Friday, reaching $115.92. The company had a trading volume of 1,304,954 shares, compared to its average volume of 887,777. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. The stock has a market capitalization of $11,360.00, a PE ratio of -21.43 and a beta of 2.68. Alnylam Pharmaceuticals has a 52 week low of $40.93 and a 52 week high of $147.63.
In other news, VP Michael Mason sold 36,745 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $131.59, for a total value of $4,835,274.55. Following the sale, the vice president now directly owns 6,352 shares of the company’s stock, valued at $835,859.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John Maraganore sold 73,415 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $130.90, for a total value of $9,610,023.50. Following the completion of the sale, the chief executive officer now directly owns 223,125 shares in the company, valued at $29,207,062.50. The disclosure for this sale can be found here. Insiders sold 220,409 shares of company stock worth $28,667,017 over the last ninety days. Corporate insiders own 4.30% of the company’s stock.
Several large investors have recently modified their holdings of ALNY. BlackRock Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 16.4% in the fourth quarter. BlackRock Inc. now owns 7,115,063 shares of the biopharmaceutical company’s stock worth $903,969,000 after acquiring an additional 1,003,366 shares during the last quarter. Janus Henderson Group PLC acquired a new position in Alnylam Pharmaceuticals during the second quarter worth $53,226,000. Orbimed Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 69.7% during the third quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock worth $127,453,000 after buying an additional 445,600 shares during the last quarter. Swiss National Bank boosted its stake in Alnylam Pharmaceuticals by 136.8% during the fourth quarter. Swiss National Bank now owns 326,500 shares of the biopharmaceutical company’s stock worth $41,482,000 after buying an additional 188,600 shares during the last quarter. Finally, Broadfin Capital LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter worth $14,453,000. 88.39% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/10/alnylam-pharmaceuticals-alny-price-target-cut-to-118-00-by-analysts-at-morgan-stanley.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.